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ABSTRACT
Background and Objectives: The effectiveness of angiotensin II receptor blockers (ARBs) 
compared with angiotensin converting enzyme inhibitors (ACEIs) in patients with acute 
myocardial infarction (AMI) has not been established. We investigated the effects of ARBs on 
clinical outcomes after percutaneous coronary intervention (PCI) in AMI patients.
Methods: Patients receiving ACEIs or ARBs after AMI treated with PCI between January 
2005 and December 2014 were selected from the Korean National Health Insurance Service 
database. The primary endpoint was major cardiovascular adverse event (MACE; all-cause 
death, myocardial infarct [MI], or stroke).
Results: We included patients regularly taking ACEIs (n=22,331) or ARBs (n=28,533) 
(medication possession ratio ≥80%). Compared with the ACEI group, the ARB group 
contained more females (31% vs. 18%), were older (mean, 63 vs. 60 years), and had more 
comorbidities, including hypertension (62.8% vs. 44.8%), diabetes (33.9% vs. 26.4%), 
congestive heart failure (7.9% vs. 4.3%), chronic obstructive pulmonary disease (25.5% 
vs. 18.9%), and end-stage renal disease (1.3% vs. 0.4%) (p<0.001 for all). After propensity 
score–matching, ARBs were associated with a 23% lower risk of MACE (hazard ratio [HR], 
0.774; 95% confidence interval [CI], 0.715–0.838; p<0.001) than ACEIs. ARB use was also 
associated with a significantly reduced risk of death (HR, 0.741; 95% CI, 0.659–0.834; 
p<0.001), MI (HR, 0.731; 95% CI, 0.638–0.837; p<0.001), and revascularization (HR, 0.816; 
95% CI, 0.773–0.861; p<0.001).
Conclusions: ARB use was associated with a lower risk of MACE, MI, and revascularization 
than ACEIs in our retrospective analysis of AMI patients who underwent PCI.
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INTRODUCTION
Chronic activation of the renin-angiotensin-aldosterone system (RAAS) plays an important 
role in the pathogenesis of cardiovascular diseases, and inhibition of RAAS reduces 
cardiovascular mortality and morbidity across a wide spectrum of cardiovascular disorders.1)2) 
Specifically, increased angiotensin II levels after myocardial infarction (MI) exert adverse 
cardiovascular effects through vasoconstriction, fluid retention, sympathetic nerve system 
activation, platelet activation, and myocardial remodeling.3)4)
RAAS blockade is accomplished therapeutically by two main groups of medications that 
have different pharmacologic actions: angiotensin converting enzyme inhibitors (ACEIs) 
and angiotensin II receptor blockers (ARBs).1)2) ACEIs suppress not only the production of 
angiotensin, but also prevent the breakdown of bradykinin, thereby inducing additional 
cardioprotective effects. In contrast, ARBs reduce RAAS activity by selective inhibition of 
angiotensin II receptors.
Use of ACEIs after MI has been demonstrated to slow the progression of heart failure and 
reduce the occurrence of cardiovascular events. International guidelines recommend early 
use of ACEIs after an acute myocardial infarction (AMI), especially in patients with heart 
failure, hypertension, diabetes, or ST segment elevation MI.5-7) However, ACEIs may produce 
cough, altered taste, or rash leading to dose reduction or permanent discontinuation of the 
medication, and drug discontinuation is more frequent with these drugs than with ARBs. 
ACEI intolerance is especially common in Asians, occurring in up to 20% of patients.8)
ARBs are currently recommended for patients intolerant to ACEI therapy.9)10) In two 
randomized controlled trials, ARBs and ACEIs exhibited similar efficacy for the prevention 
of death and cardiovascular morbidities after AMI.11)12) However, clinical evidence in support 
of the use of ARBs in patients with AMI remains limited. In the present study, we used 
claims data from the Korean National Health Insurance Service (KNHIS) to compare clinical 
outcomes in real-world practice between the use of ARBs or ACEIs after AMI in patients who 
underwent percutaneous coronary intervention (PCI) with stent insertion.
METHODS
Study population
This is a retrospective cohort study using claims data from KNHIS, which is the sole 
insurer of the Korean national health insurance program. KNHIS operates a medical claims 
database that includes diagnoses, treatments, pharmaceuticals, and procedures, as well 
as personal data, such as age, sex, residential area, and date of death. All medical service 
providers and people seeking medical services in Korea are required by national acts to join 
the KNHIS insurance program. Therefore, the KNHIS database covers almost all medical 
services performed in the Korean population since 2002. The database is based on the 
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Korean Standard Classification of Disease-7 coding system, which is compatible with the 
International Classification of Diseases-10 coding system.
For the present study, we included all patients in the KNHIS database who underwent PCI 
using a bare metal stent or drug-eluting stent (DES) from 2005 to 2014 while admitted to 
a hospital under new diagnosis of AMI (diagnostic codes: I21, I22, or I23). The exclusion 
criteria were coronary bypass surgery, PCI without stent insertion, cardiopulmonary 
resuscitation, in-hospital death during the index admission, or the presence of metastatic 
cancer. We also excluded patients who received no antiplatelet agents after the index PCI to 
minimize confounding factors. The study population was followed after stent implantation 
for 2 years or until the primary end point occurred.
Data collection and outcome assessments
Data were collected by analyzing diagnostic, prescription, and procedural codes in the claims 
database. We calculated the medication possession ratio (MPR) by dividing the sum of days 
for which a medication was prescribed by the number of follow-up days. We classified the 
study population as regular medication users (MPR ≥80%), irregular medication users (MPR 
1%–79%), or non-users (MPR 0%).13) Only regular users of the respective medications were 
included in the outcome comparisons between the ARB and ACEI groups. Patients receiving 
both ACEIs and ARBs and those who changed medications from 1 group to the other during 
follow-up were excluded from the clinical outcomes comparisons. We defined the index time 
point as the date of admission for the procedure.
The primary end point was major adverse cardiovascular event (MACE), defined as the 
composite of all-cause death, myocardial infarction, or stroke (all types). MI was considered 
to have recurred during follow-up if the main diagnosis of AMI (diagnostic codes: I21, I22, or 
I23) was combined with rehospitalization and coronary angiography (procedure code: HA670) 
or if a new diagnosis of sudden cardiac arrest (diagnostic code: I469) was confirmed. We 
adopted this narrow definition of AMI to avoid misdiagnosis of a previous MI as a new event 
during follow-up. Strokes included ischemic stroke, hemorrhagic stroke, or unknown type of 
stroke (diagnostic codes: I60, I61, I62, I63, or I64) that were confirmed with an imaging study 
(examination codes: HE101, 201, 135, 235, 236, 451, or 461) during hospitalization.
Statistical analysis
χ2 tests or Fisher's exact tests were used to compare categorical variables; Student's t-tests 
were used to compare continuous variables. Univariate and distributional analyses included 
measures of clinical outcomes. For propensity-score matching, we performed 1:1 case-control 
matching based on the propensity score with a hierarchical sequence until there were no 
more further matches. SAS logistic procedure code was used to create the propensity scores. 
The variables included in the propensity score matching were following confounding factors: 
age, sex, year of study enrollment, hypertension, diabetes mellitus, dyslipidemia, previous 
stroke, previous MI, heart failure, history of malignancy, stent type, number of stents, and in-
hospital and follow-up medications (dual antiplatelet agents, beta blockers, calcium channel 
blockers, statins, loop diuretics, and spironolactone). Cox proportional-hazards regression 
analysis was used to assess the effects of ACEIs or ARBs as independent predictors of MACE. 
Statistical analysis was performed using SAS software (SAS Institute, Ver 9.1, Cary, NC, USA). 
The statistical significance level was set at p<0.05.
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RESULTS
Baseline characteristics
We identified a total of 108,728 patients who met the study inclusion criteria from January 
2005 to December 2014. Of these, 84,260 (77.5%) patients were prescribed one or more 
RAAS blockers at hospital discharge and 68,459 (62.96%) patients were regular RAAS blocker 
users during the 2-year follow-up period (Figure 1). After excluding 17,595 patients who were 
prescribed both ARBs and ACEIs or who converted from an ARB to an ACEI or from an ACEI 
to an ARB during follow-up, we enrolled 50,864 regular users of either an ARB (n=28,533) or 
an ACEI (n=22,331) in this study.
Overall, the mean age of the study population was 62 years, and 74% of the included patients 
were male. Baseline characteristics, implanted stents, and prescribed medications for the 
two patient groups are summarized in Table 1. Compared with the ACEI group, the ARB 
group contained more females (31% vs. 18%, p<0.001) and was older (mean age, 63 years vs. 
60 years, p<0.001). In addition, several comorbidities were more frequent in the ARB group 
than in the ACEI group: hypertension (62.8% vs. 44.8%, p<0.001), DM (33.9% vs. 26.4%, 
p<0.001), CHF (7.9% vs. 4.3%, p<0.001), chronic obstructive pulmonary disease (25.5% vs. 
18.9%, p<0.001), and end-stage renal disease (1.3% vs. 0.4%, p<0.001) (Table 1).
After performing propensity-score matching for the entire population, we obtained 19,762 
matched pairs of ARB users and ACEI users (Table 2). Standardized differences between 
propensity-matched groups were <0.1 for all baseline characteristics and medications. The 
ARBs and ACEIs prescribed for the study population were presented in Supplementary Table 1.
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AMI patients who underwent PCI using stent
January 2005–December 2014
Exclusion criteria:




• No antiplatelet therapy
Excluded (n=17,595)
















Figure 1. Flow diagram of the study population. 
ACEI = angiotensin converting enzyme inhibitor; AMI = acute myocardial infarction; PCI = percutaneous coronary 
intervention; RAAS = renin–angiotensin–aldosterone system.
Clinical outcomes
In non-matched comparisons, the ARB and ACEI groups had similar rates of MACE (6.5% 
vs. 6.8%, hazard ratio [HR], 0.947; 95% confidence interval [CI], 0.885–1.014), as well as 
individual clinical events, including all-cause death, MI, stroke, and revascularization (Table 3).  
However, in matched comparisons, the ARB group had a 23% lower risk of MACE (HR, 
0.770; 95% CI, 0.711–0.834; p<0.001), compared with the ACEI group. The ARB group also 
had significantly lower risks of all-cause death (HR, 0.743; 95% CI, 0.66–0.835; p<0.001), 
MI (HR, 0.727; 95% CI, 0.635–0.833; p<0.001), and revascularization (HR, 0.821; 95% CI, 
0.759–0.845; p<0.001) (Table 4).
In a Cox proportional hazard multivariate regression model, ARB was identified as an 
independent protective factor for MACE (HR, 0.781; 95% CI, 0.727–0.839; p<0.0001) 
(Table 5). Other determinants for MACE were age, male gender, hypertension, diabetes, 
dyslipidemia, previous stroke, congestive heart failure, chronic obstructive pulmonary 
disease, endstage renal disease, history of malignancy, bare metal stent, 1st generation drug-
eluting stent, number of implanted stents ≥2, dualantiplatelet agents, non-use of antiplatelet 
agent, use of statin, loop diuretics, aldactone, and vasodilators.
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Table 1. Baseline characteristics of ACEI or ARB users
Characteristic ARB group (n=28,533) ACEI group (n=22,331) p
Age (years) 63±12 60±12 <0.001
Male 19,711 (69.1) 18,408 (82.4) <0.001
Study enrollment <0.001
2005–2008 8,411 (29.5) 8,610 (38.6)
2009–2011 8,786 (30.8) 6,702 (30.0)
2012–2014 11,336 (39.7) 7,019 (31.4)
Comorbidities
Hypertension 17,915 (62.8) 10,012 (44.8) <0.001
DM 9,657 (33.9) 5,891 (26.4) <0.001
Dyslipidemia 9,617 (33.7) 5,626 (25.2) <0.001
Previous stroke 2,884 (10.1) 1,595 (7.1) <0.001
CHF 2,255 (7.9) 948 (4.3) <0.001
COPD 7,278 (25.5) 4,216 (18.9) <0.001
ESRD 372 (1.3) 84 (0.4) <0.001
History of malignancy 934 (3.3) 658 (2.9) 0.036
Type of stent <0.001
BMS 1,025 (3.6) 1,247 (5.6)
1st generation DES 7,329 (25.7) 6,957 (31.2)
2nd generation DES 20,179 (70.7) 14,127 (63.3)
Number of stents 0.725
1 23,485 (82.3) 18,407 (82.4)
2 or more 5,048 (17.7) 3,924 (17.6)
Medications during follow-up
Dual antiplatelet agents (aspirin plus clopidogrel) 17,077 (59.9) 13,554 (60.7) <0.001
Aspirin only 7,827 (27.4) 6,295 (28.2)
Clopidogrel only 3,312 (11.6) 2,310 (10.3)
Beta blocker 20,291 (71.1) 17,619 (78.9) <0.001
Statin 24,381 (85.5) 19,237 (86.1) 0.026
Loop diuretic 3,564 (12.5) 2,322 (10.4) <0.001
Aldactone 1,606 (5.6) 1,432 (6.4) 0.002
Vasodilator 9,753 (34.2) 8,040 (36.0) <0.001
Number of antihypertensives 1.93±0.63 1.86±0.49 <0.001
Values are expressed as number (%), or mean±standard deviation.
ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor II blocker; BMS = bare metal stent; 
CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; DES = drug-eluting stent; DM = 
diabetes mellitus; ESRD = end-stage renal disease; SD = standard deviation.
DISCUSSION
In this retrospective study using KNHIS claims data, we found that patients with AMI treated 
with PCI were more frequently prescribed ARBs than ACEIs. Furthermore, patients treated 
with ARBs had significantly lower rates of adverse clinical events, including MACE, all-cause 
death, MI, and revascularization, than those treated with ACEIs.
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Table 2. Baseline characteristics of ACEI or ARB users after propensity-score matching
Characteristic ARB group (n=19,762) ACEI group (n=19,762) SD p
Age (years) 61±12 61±12 0.00 <0.001
Male 15,960 (80.7) 15,872 (80.3) −0.01 <0.001
Study enrollment 0.581
2005–2008 6,842 (34.6) 6,886 (34.8) 0.00
2009–2011 6,045 (30.6) 6,099 (30.9) 0.00
2012–2014 6,875 (34.8) 6,777 (34.3) −0.01
Comorbidities
Hypertension 9,901 (50.1) 9,829 (49.7) −0.01 0.820
DM 5,526 (27.9) 5,574 (28.2) 0.00 <0.001
Dyslipidemia 5,360 (27.1) 5,402 (27.3) 0.00 <0.001
Previous stroke 1,509 (7.6) 1,545 (7.8) 0.01 <0.001
CHF 912 (4.6) 937 (4.7) 0.01 <0.001
COPD 3,984 (20.2) 4,036 (20.4) 0.01 <0.001
ESRD 76 (0.4) 83 (0.4) 0.01 <0.001
History of malignancy 623 (3.2) 613 (3.1) 0.00 <0.001
Type of stent 0.729
BMS 859 (4.4) 891 (4.5) 0.01
1st generation DES 5,770 (29.2) 5,773 (29.2) 0.00
2nd generation DES 13,133 (66.5) 13,098 (66.3) 0.00
Number of stents <0.001
1 16,380 (82.9) 16,303 (82.5) −0.01
2 or more 3,382 (17.1) 3,459 (17.5) 0.01
Medications during follow-up
Dual antiplatelet agents (aspirin plus clopidogrel) 11,930 (60.4) 11,880 (60.1) 0.00 0.760
Aspirin only 5,607 (28.4) 5,592 (28.3) 0.00
Clopidogrel only 2,057 (10.4) 2,123 (10.7) 0.01
Betablocker 14,821 (75.0) 15,019 (76.0) 0.00 <0.001
Statin 17,107 (86.6) 17,015 (86.1) −0.01 <0.001
Loop diuretic 2,063 (10.4) 2,147 (10.9) 0.01 <0.001
Aldactone 1,173 (5.9) 1,198 (6.1) 0.00 <0.001
Vasodilator 6,884 (34.8) 6,976 (35.3) 0.01 <0.001
Number of antihypertensives 1.8±0.60 1.88±0.48 0.00 <0.001
Values are expressed as number (%), or mean±standard deviation.
ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor II blocker; BMS = bare metal stent; CHF = congestive heart failure; COPD = chronic 
obstructive pulmonary disease; DES = drug-eluting stent; DM = diabetes mellitus; ESRD = end-stage renal disease; SD = standard deviation.
Table 3. Number of events after percutaneous coronary intervention with stent insertion in patients with acute MI 
before propensity-score matching
Clinical events ARB group (n=28,533) ACEI group (n=22,331) Hazard ratio (95% CI)*
MACE 1,870 (6.5) 1,513 (6.8) 0.947 (0.885–1.014)
All-cause death 937 (3.3) 682 (3.1) 1.052 (0.953–1.161)
MI 554 (1.9) 577 (2.6) 0.737 (0.656–0.828)
Stroke 431 (1.5) 299 (1.3) 1.105 (0.953–1.280)
MI or stroke 980 (3.4) 873 (3.9) 0.861 (0.786–0.943)
Revascularization 3,409 (12.2) 3,376 (15.1) 0.772 (0.736–0.809)
Values are expressed number (%).
ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor II blocker; CI = confidence interval; 
MACE = major adverse cardiovascular event; MI = myocardial infarction.
*Compared with ACEI as the reference.
Although both ARBs and ACEIs modulate the RAAS, these drugs have different action 
mechanisms which may lead to different effects on cardiovascular outcomes in AMI 
patients. ACEIs not only block the conversion of angiotensin I to angiotensin II but also 
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Table 4. Clinical outcomes after propensity score matching
Clinical events
ARB ACEI
HR of ARB 95% CI p







MACE 3,146.1 1,085 0.06 4,076.6 1,365 0.08 0.774 0.715–0.838 <0.0001
All death 1,420.8 490 0.03 1,917.3 642 0.04 0.741 0.659–0.834 <0.0001
MI 1,061.3 366 0.02 1,460.4 489 0.03 0.731 0.638–0.837 <0.0001
Stroke 742.3 256 0.01 833.2 279 0.02 0.894 0.754–1.059 0.1949
MI or stroke 1,794.9 619 0.03 2,284.7 765 0.04 0.789 0.71–0.877 <0.0001
Revascularization 7,118.7 2,455 0.13 8,753.5 2,931 0.15 0.816 0.773–0.861 <0.0001
All rehospitalization 23,762.7 8,195 0.46 24,265.4 8,125 0.45 0.969 0.939–0.999 0.0419
ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor II blocker; CI = confidence interval; HR = hazard ratio; MACE = major adverse 
cardiovascular event; MI = myocardial infarction.
*Events at 100 patient years.
Table 5. Univariate and multivariate predictors of major adverse cardiovascular event after coronary stenting after AMI
Risk factors
Univariate Multivariate
HR 95% CI p HR 95% CI p
Age 1.055 1.052–1.058 <0.0001 1.045 1.042–1.049 <0.0001
Male 0.636 0.593–0.683 <0.0001 1.189 1.101–1.285 <0.0001
Study enrollment
2005–2008 1 - - 1 - -
2009–2011 0.809 0.746–0.878 <0.0001 1.084 0.976–1.204 0.1334
2012–2014 0.744 0.686–0.807 <0.0001 0.984 0.874–1.109 0.7944
Underlying medical condition
Hypertension 2.003 1.861–2.157 <0.0001 1.138 1.046–1.239 0.0028
DM 1.826 1.706–1.954 <0.0001 1.323 1.229–1.425 <0.0001
Dyslipidemia 1.182 1.1–1.27 <0.0001 0.919 0.851–0.992 0.0304
Previous stroke 2.436 2.233–2.657 <0.0001 1.484 1.355–1.624 <0.0001
CHF 2.573 2.336–2.835 <0.0001 1.344 1.213–1.49 <0.0001
COPD 1.678 1.562–1.804 <0.0001 1.140 1.057–1.228 0.0006
ESRD 5.973 5.057–7.054 <0.0001 4.152 3.484–4.946 <0.0001
History of malignancy 2.117 1.84–2.435 <0.0001 1.621 1.407–1.869 <0.0001
Type of stent
BMS 1.827 1.596–2.091 <0.0001 1.723 1.491–1.991 <0.0001
1st generation DES 1.369 1.273–1.472 <0.0001 1.290 1.157–1.438 <0.0001
2nd generation DES 1 - - 1 - -
Number of stents
1 1 - - 1 - -
≥2 1.025 0.938–1.118 0.5885 0.852 0.777–0.934 0.0007
Medication
Antiplatelet agents
Dual antiplatelet agents 4.691 4.182–5.262 <0.0001 4.128 3.677–4.634 <0.0001
Clopidogrel only 1.331 1.106–1.6 0.0024 1.178 0.979–1.418 0.0835
Aspirin only 1 - - - - -
No antiplatelet agents 4.465 3.298–6.046 <0.0001 2.985 2.201–4.05 <0.0001
ARB (compared with ACEI) 0.947 0.885–1.014 0.1172 0.781 0.727–0.839 <0.0001
Beta blocker 0.839 0.779–0.904 <0.0001 1.027 0.844–1.25 0.7888
CCB 0.919 0.815–1.037 0.1695 0.800 0.692–0.925 0.0026
Statin 0.513 0.475–0.555 <0.0001 0.653 0.602–0.709 <0.0001
Loop diuretics 2.745 2.54–2.967 <0.0001 1.502 1.374–1.641 <0.0001
Aldactone 2.393 2.16–2.651 <0.0001 1.401 1.251–1.57 <0.0001
Vasodilators 1.444 1.348–1.545 <0.0001 1.198 1.118–1.284 <0.0001
ACEI = angiotensin converting enzyme inhibitor; AMI = acute myocardial infarction; ARB = angiotensin receptor II blocker; BMS = bare metal stent; CCB = calcium 
channel blocker; CI = confidence interval; CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; DES = drug-eluting stent; DM = 
diabetes mellitus; ESRD = end-stage renal disease; HR = hazard ratio.
the degradation of bradykinin by inhibition of angiotensin-converting enzyme.1)2) Thereby, 
ACEIs decrease the formation of angiotensin II, a potent vasopressor, but increase the level 
of bradykinin, a vasodilator. However, long-term treatment with ACEIs leads to a gradual rise 
of circulating angiotensin II concentration to pretreatment levels, a phenomenon described 
as “angiotensin II escape.”14) Angiotensin II production by other enzymes in the tissues may 
be responsible for this phenomenon. In contrast, ARBs directly target on the angiotensin 
type 1 receptor (AT1R).15) The selective action on the attenuated total internal reflection leads 
to unopposed stimulation of angiotensin type 2 receptor, which in turn counteracts the 
vasoconstrictive effects due to AT1R stimulation.13) However, ARBs bypass the bradykinin 
pathway and may lack potential cardiovascular protective effects of bradykinin. On the other 
hand, ARBs do not induce cough or angioedema by accumulation of bradykinin.16)
Recent meta-analyses demonstrated that ACEIs and ARBs have similar effectiveness 
for preventing major cardiovascular outcomes, such as AMI, stroke, and heart failure 
or hospitalization, although ACEIs are more effective for reducing total deaths and 
cardiovascular deaths.17-19) However, only 2 randomized controlled trials have compared 
ARBs versus ACEIs for preventing mortality and morbidity after AMI.11)12) The Optimal Trial 
in Myocardial Infarction with the Angiotensin II Antagonist Losartan (OPTIMAAL),11) which 
compared losartan with captopril in patients with AMI and symptoms of heart failure or left 
ventricular dysfunction, found no significant differences between the 2 drugs for all-cause 
mortality and cardiovascular events, although there was a trend towards lower mortality in 
the captopril group. In the Valsartan in Acute Myocardial Infarction (VALIANT) trial,12) which 
compared valsartan with captopril in patients with heart failure or left ventricular systolic 
dysfunction after AMI, valsartan was non-inferior to captopril with regard to total mortality 
and fatal or non-fatal adverse cardiovascular events. Based on these trials, current guidelines 
recommend ACEIs as first-choice treatment after AMI in patients with heart failure and/
or left ventricular dysfunction, with ARBs considered an alternative for ACEI-intolerant 
patients.9)10)20)21) However, these trials were conducted in the early 2000s; reperfusion therapy 
was performed in only approximately 10% and 30% of subjects in the OPTIMAAL11) and 
VALIANT12) trials, respectively; and the statin prescription rate was only 30%. Thus, these 
trials may not reflect contemporary clinical practice for the treatment of AMI.
In recent years, several retrospective cohort studies comparing ARB and ACEI use after 
AMI reported inconsistent results. Hara et al. found that ACEIs were associated with better 
survival than ARBs.22) Similarly, Korean investigators such as Ann et al.23) and Choi et al.24) 
also demonstrated improved survival with ACEIs. By contrast, Lee et al.25) reported that ARBs 
were superior to ACEIs for preventing in-hospital mortality and 12-month MACE, findings 
compatible with our study results. Other Korean data by Yang et al.26) showed comparable 
effectiveness of ARBs and ACEIs. Unlike the randomized controlled trials, these cohort 
studies included patients both with and without heart failure or left ventricular dysfunction 
after AMI.19)22-26) The percentages of patients with heart failure or Killip class II/IV in these 
cohort studies ranged from 2.2% to 18.1%. In the present study, approximately 6% of enrolled 
patients had congestive heart failure. Thus, the results of the cohort studies cannot be directly 
compared with those of the randomized control trials. A recent meta-analysis reported that 
ARBs effectively reduce cardiovascular mortality and morbidity in patients without heart 
failure; although studied in a non-AMI setting,27) these findings are consistent with the results 
of our study. Previously, several studies reported increased cardiovascular events in patients 
treated with ARBs, suggesting the existence of an ARB MI paradox.28) We did not observe an 
increased risk of cardiovascular events with ARB use in the present analysis.
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Our study has several strengths. Firstly, it represents data from essentially all patients with 
an AMI treated with PCI (including stent insertion) in Korea between 2005 and 2014, which 
included >100,000 patients. This is the largest study population reported so far. Secondly, 
all clinical events during the follow-up period were captured; collecting data from the 
KNHIS database minimized loss of outcome information. Thirdly, our study differs from the 
previous studies in the study design. The previous studies categorized patient groups based 
on hospital discharge medication. However, in our study, the patient groups were analyzed 
based on the outpatient prescription for a 2-year follow-up period. Furthermore, this study 
accounted for treatment compliance by including only patients with an MPR ≥80% when 
comparing outcomes of ARBs versus ACEIs. No prior cohort study accounted for compliance 
in their analyses. Ortolani et al.29) reported that poor adherence to ACEI or ARB prescription 
medication was associated with a 20% increased risk of recurrent AMI. We further excluded 
17,595 patients who received both ACEIs and ARBs during the follow-up period. Among 
them, 84.3% changed the medication from an ACEI to an ARB. Thus, discharge medication 
may not represent the actual medication the patients take for long term. In the OPTIMAAL 
study, ARBs were significantly better tolerated than ACEIs, with fewer patients discontinuing 
study medication.11) The relatively high rate of conversion from ACEI to ARB observed in our 
study likely reflects the previously reported higher rate of ACEI intolerance in Asians.8)
Our study also has limitations. Firstly, this is a retrospective observational study. The 
possibility of bias cannot be excluded, despite the use of propensity score–matching to 
adjust for known potential confounding factors. Secondly, in this study, we included all 
patients who underwent PCI using stents under new diagnosis of MI. However, since cardiac 
biomarker or electrocardiogram data were not available, the accuracy of MI diagnosis 
remains uncertain. Furthermore, MI was considered to have recurred during follow-up if 
the diagnosis of MI was combined with rehospitalization and coronary angiography or if 
a new diagnosis of sudden cardiac arrest was confirmed. However, some of these patients 
might have been rehospitalized and have undergone coronary angiography for reasons other 
than recurred MI. Thus, the rate of recurred MI might have been overestimated. Thirdly, we 
were unable to obtain important laboratory, angiography or echocardiography data. Thus, 
we could not accurately determine cardiovascular disease status or heart failure severity, 
although we tried to adjust for left ventricular systolic dysfunction by identifying patients 
prescribed loop diuretics or spironolactone. In addition, there might have been also other 
confounding factors that were not included in the KNHIS database. Lastly, we were unable to 
collect information about the dosage of ACEIs or ARBs, which also may have impact on the 
clinical outcomes.
In conclusion, ARB use was associated with lower rates of MACE, MI, and revascularization 
than ACEIs in our retrospective analysis of a large, diverse group of patients with AMI treated 
with PCI in Korea. Further clinical trials are required to validate our findings.
SUPPLEMENTARY MATERIAL
Supplementary Table 1
Frequency of ACEIs and ARBs prescribed in the study population
Click here to view
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